"label","name","uuid:ID","rationale","description","id","instanceType"
"","Study Design 1","03f58381-f036-4ae5-80ca-86a8cb98700c","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","StudyDesign_1","StudyDesign"
